Bespak, a developer and manufacturer of specialty drug delivery and medical devices, has recently commemorated the manufacture of the 300 millionth Diskus device for GlaxoSmithKline
The event was marked with a special ceremony at Bespak's manufacturing facility in King's Lynn attended by Steve Bucksey, VP procurement (new product and global supply) and other key representatives from GlaxoSmithKline.
Bucksey addressed Bespak's operations staff and senior management team and awarded a specially made plaque to mark this key milestone.
In return, Bespak presented Bucksey with a solid stainless steel replica of the Diskus device.
Steve Bucksey commented "This is a significant milestone for Bespak and I wanted to thank the team here for the support in development, launch, quality and delivery that they have afforded us over the last 12 years on this key device." Bespak manufacturers the dry powder inhaler for GlaxoSmithKline and the device is employed to deliver a number of asthma therapies including the combination beta-agonist and corticosteroid drug Seretide/Advair; fast becoming GSK's most successful drug product.
Bespak began manufacture of the device in 1995 and following the overwhelming global success of the product, especially in Europe and the USA, Bespak has continually evolved its manufacturing capability to meet demand.
"To have consistently delivered the volumes required while also fulfilling the necessary regulatory compliances and high quality requirements for this device is a real success story." Said Phil Lever, head of commercial at Bespak.
Diskus is known as Accuhaler in Europe and Advair is recognised under the brand name of Seretide.
